CDSCO Panel Recommends Approval for Vorasidenib with Phase-III Waiver, Mandates Phase-IV Trial in India
August 5, 2025
- NMC slams medical colleges over errors in MBBS admission entries, calls for rectification
- Bristol Myers Squibb Breyanzi application accepted for priority review by USFDA for Marginal Zone Lymphoma
- HC Slams Kerala Govt for withholding Rs 46 Crore Compensation for Covid Facility Use
- Cipla Bommasandra facility gets VAI classification from USFDA
Headlines
